Zealand Pharma has acquired FDA approval for Zegalogue® (dasiglucagon) injection for the therapy of extreme hypoglycemia in pediatric and grownup sufferers with diabetes aged 6 years and above. Severe hypoglycemia is an acute, life-threatening situation ensuing from a crucial drop in blood...
This content material initially appeared on Beyond Type 1. Republished with permission. By Lala Jackson On March 22, 2021, Zealand Pharma introduced the FDA approval of Zegalogue in an autoinjector and prefilled syringe. The approval will add two extra easy-to-use glucagon choices, becoming...
The U.S. FDA has introduced clearance of an expanded pediatric indication for the Tandem’s t:slim X2™ insulin pump with Control-IQ™ know-how to kids age 6 and older. The product was beforehand authorised for ages 14 and older. Control-IQ know-how is a sophisticated hybrid closed-loop function designed...
The U.S. Food and Drug Administration (FDA) has authorized a brand new synthetic pancreas system — designed to robotically monitor and regulate blood glucose ranges in folks with sort 1 diabetes — primarily based partially on the outcomes of a latest...
Dapagliflozin (Farxiga) has been permitted within the US as a remedy to reduce the risk of hospitalisation for heart failure. The US Food and Drug Administration (FDA) permitted this particular use of the drug for people with type 2 diabetes which...
The U.S. Food and Drug Administration (FDA) has permitted the primary oral GLP-1 medication for blood sugar administration in adults with kind 2 diabetes. Manufactured by Novo Nordisk, Rybelsus (semaglutide) oral tablets are the primary drug of their class that don’t...
The first glucagon-like peptide-1 (GLP-1) receptor agonist in pill type has been permitted for individuals with type 2 diabetes within the US. Rybelsus, (remedy identify semaglutide) has been permitted by the US’s official medicine physique the Food and Drug Administration (FDA)....
TheU.S. FDA has permitted Rybelsus (semaglutide), the primary and solely glucagon-like peptide-1 (GLP-1) analog in a capsule. “GLP-1 receptor agonists are effective medications for people with type 2 diabetes but have been underutilized in part because they have, until now, only been...
On the heels of the approval of nasal glucagon, the FDA has accepted Xeris Pharmaceuticals’ ready-to-use, room-temperature steady liquid glucagon, GVOKE (glucagon) injection, for the therapy of extreme hypoglycemia in folks with diabetes ages 2 years and above. GVOKE is the primary...
The U.S. Food and Drug Administration (FDA) has authorised Lilly’s BAQSIMI (glucagon) nasal powder three mg for the remedy of extreme hypoglycemia in individuals with diabetes ages 4 years and above. BAQSIMI is the primary and solely nasally administered glucagon, and...
